QualityDipStocks / Consumer Discretionary · Business Services
Akso Health Group ADS AHG
Outside our quality screen, so we don’t track its dips. It’s 48% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −48%
- Risk vs market
- Lowbeta −0.10
52-week range 34% of the way from its 52-week low to its high
Price $1.31
1 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for AHG: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much AHG moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 7.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- -0.10
- Volatility
- 96% vs 13% SPY
- Correlation SPY
- −0.01
- Correlation QQQ
- 0.01
How it ranks
Where AHG stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Free cash flow yield−1.2% · free cash flow vs market capLowest 17%of 1,690
- Revenue growth, last 12 months−6.4% · vs the 12 months beforeLowest 5%of 2,184
- Operating margin−150% · of sales kept as operating profitLowest 1%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ProfitabilityOperating margin widened to −149.7% in FY2026 from −357.8% in FY2024 (SEC filings).
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$13M over the last 12 months), so there’s no cash-flow value under the price.
GrowthDiluted EPS fell 94% to $0.01 in FY2026.
ProfitabilityLost $19M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −150% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter; debt load unclear or high.
All fundamentals
FCF yield -1.2% · ROE -10% · Sales −6%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −1.2%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 79.53×
- Price / book
- 6.08×
- Market cap
- $1.1Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $14M
- Sales growth, 12 months
- −6.4%vs the 12 months before
- Sales growth, 3 yrs
- +1.6%/yrfrom FY2023
- Diluted EPS, 12 months
- $0.01
- EPS growth, last FY
- −93.8%
- Net income, 12 months
- −$19M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- −0.1%
- Operating margin
- −149.7%
- Net margin
- −135.0%
- FCF margin
- −92.5%
- Return on equity
- −10%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $170,572
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$13M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Mar 31, 2026; balance sheet at Mar 31, 2026. From Akso Health Group ADS’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.3B · Sales −13%
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield-1.2%
- Gross margin0%
- Operating margin−38%
- Return on invested capital−2%
- Return on equity−10%
- Sales growth (latest quarter vs year-ago quarter)−13%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $1.31
- 52-wk lowlowest close, 1 year$0.69−47.3%
- PriceMon Nov 2 close$1.31you are here
- 52-wk highhighest close, 1 year$2.50+90.8%
Momentum & 52-week range
RSI 57 · 5 days +3.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
AHG is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Akso Health Group ADS in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Business Services
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.